Silence Therapeutics PLC (LON:SLN) has made two key appointments that will respectively strengthen the board and the business.
Dave Lemus, currently chief operating officer and chief financial officer of Proteros Biostructures, has been appointed an independent director.
Chairman Annalisa Jenkins said: "Dave has joined at a pivotal time for the company. His successful track record and proven leadership in building and managing high performance management teams will strengthen our capabilities as we continue to maximise the potential of our GalNAc-based SRNi platform."
Meanwhile, Richard Jenkins comes on board as head of clinical development, replacing chief scientific officer Torsten Hoffmann who is leaving Silence for personal reasons.
Jenkins, who has worked for Takeda and GlaxoSmithKline, will oversee the development of the company's main drug candidate, a compound for iron overload, as it progresses towards clinical trials. He will report directly to chairman Jenkins.